Mayne Pharma (ASX:MYX) share price dives 16% on FDA update

The Mayne Pharma share price has dropped nearly 16% today following an FDA update. We take a closer look at the FDA response.

| More on:
falling asx share price represented by piggy bank wearing doctor's mask having fallen over

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has not been a great day for Mayne Pharma Group Ltd (ASX: MYX) shareholders. The Mayne Pharma share price has tanked today following a setback on its new drug application for a generic version of Nuvaring.

At the time of writing, the Mayne Pharma share price is heavily down 15.79% to 32 cents.

What does Mayne Pharma do?

Mayne Pharma is a pharmaceutical company that focuses on the delivery and commercialisation of branded and generic drugs. The technology-driven business provides contract development and manufacturing services to more than 100 clients worldwide. Its global reach spans across Australia, North America, Europe and Asia. The business is supported by over 900 staff and 200 scientists formulating new oral and topical drugs.

What happened?

The Mayne Pharma share price has, to a lesser extent, today mimicked the fall of Mesoblast Limited (ASX: MSB) last week when that company received its own update from the United Stated Food and Drug Administration (FDA). As was the case with Mesoblast, the FDA issued a complete response letter to Mayne Pharma.

The FDA has raised questions in relation to the company's generic version of the drug Nuvaring. In response, Mayne Pharma advised it was working closely with its development partner, Mithra Pharmaceuticals to address the issues.

Mayne Pharma noted that following its resolution of the FDA's concerns, a new target action date will be set for its new drug application (NDA).

Mayne Pharma CEO, Scott Richards, remains driven to have the company's generic Nuvaring drug available to the market. He said:

We are confident we can address the issues raised in the letter in a timely manner. Pleasingly, the FDA has indicated that Mayne Pharma and its development partner Mithra have an acceptable manufacturing process for generic Nuvaring. Furthermore, the market opportunity continues to be highly attractive with only one independent generic approved and an addressable market of US$920m.

In addition to the news, the company also participated in a mid-cycle review meeting with the FDA regarding its Nextstellis drug. Mayne Pharma stated that it did not receive notification of any significant issues or major safety concerns. The company said that the meeting signalled the halfway mark to its NDA review process. It expects to be granted commercialisation rights of the novel oral contraceptive within six months

About the Mayne Pharma share price

The Mayne Pharma share price has risen 60% since falling to its 52-week low of 20 cents in March. Although now materially lower, before the news today, the Mayne Pharma share price was up almost 12% since the start of last month.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Broker Notes

Why DroneShield, Nickel Industries, and CSL shares could be best buys

Let's see why Bell Potter is so bullish on these shares.

Read more »

A group of executives sit in front of computer screens in a darkened room while a colleague stands giving a presentation with a share price graphic lit up on the wall
Opinions

2 ASX 200 large-cap shares that this fundie is cashing in after phenomenal growth

Shaw and Partners portfolio manager James Gerrish says he knows this will be an 'unpopular call'.

Read more »

Animation of a man measuring a percentage sign, symbolising rising interest rates.
Share Market News

Here's what Westpac says the RBA will do with interest rates next week

Are interest rates heading lower again? Let's find out what the banking giant is predicting.

Read more »

A handsome smiling man sits in the front seat of an electric vehicle with his hands on the wheel feeling pleased that the Carsales share price is going up and the company will shortly pay its biggest dividend ever
Share Market News

Are electric vehicle stocks a good investment today?

Did US President Trump just kill the EV industry?

Read more »

Hands reaching high for a trophy with a sunset in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a cracking end to the trading week for ASX investors.

Read more »

Two brokers analysing stocks.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Woman and man calculating a dividend yield.
Opinions

Buy or bail? Fundie's verdict on 2 ASX 300 shares

Stuart Bromley of Medallion Financial Group provides his insights.

Read more »

A man analyses stockmarket graph on his computer.
Share Market News

US stocks vs. ASX shares in FY25

Would you be surprised to learn that ASX tech shares rose faster than US tech stocks by almost 2:1?

Read more »